ChongQing Zhengchuan Pharmaceutical Packaging Co.,Ltd. (603976.SS)
Chongqing, CN
ChongQing Zhengchuan Pharmaceutical Packaging Co.,Ltd. specializes in the research, development, manufacturing, and sale of various glass packaging solutions for the pharmaceutical industry across China. Their extensive product line includes medium borosilicate glass ampoule and injection bottles, low borosilicate tubular vials and ampoules, oral liquid vials, and screw-neck vials. The company also provides plastic flip-off and aluminum caps, as well as borosilicate and soda-lime glass control bottles. Established in 1988, the firm's headquarters are situated in Chongqing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.19% | -16.69% | +2.41% | +3.14% | +2.90% | +12.05% | +23.35% | +10.68% | -54.90% | +47.05% | +47.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Packaging & Containers: +2.6%-17.5% Q1'26: +29.1% (vs Q1'25)
-
EPS growth Packaging & Containers: +8.0%-62.9% Q1'26: -35.4% (vs Q1'25)
-
FCF margin FCF growth · Packaging & Containers: +34.6%+9.8% Q1'26: +12.3% (vs Q1'25)
-
EBIT margin Packaging & Containers: +7.0%+4.0% Q1'26: +4.0% (vs Q1'25)
-
ROIC Packaging & Containers: +6.2%+1.7% Q1'26: +2.2% (vs Q1'25)
-
Share dilution Packaging & Containers: +0.2%-0.6% ★ Q1'26: -3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Packaging & Containers: 0.83×4.03× Q1'26: 17.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fengan Jiang | Deputy GM & Director | — | male |
| Hanrong Xiao | Chief Financial Officer & Accounting Supervisor | — | female |
| Qing Xiao | Deputy GM & Director | — | male |
| Shiping Fei | Secretary of the Board of Directors | — | male |
| Yong Fan | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603976.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
